Promacta

Phase 2Small molecule

WWeill Medical College of Cornell University

Promacta is one of 7 small molecule programs targeting Wiskott-Aldrich syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wiskott-Aldrich SyndromeActive, not recruiting

Wiskott-Aldrich SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Wiskott-Aldrich Syndrome

#DrugCompanyPhaseTrials

Tepadina

Alnylam Pharmaceuticals

Busulfex

Alkeran

Nplate

2 5

Promacta

GSK

Phase 2

1 6

Interleukin 2

EEssen Biotech

Phase 1

1 7

Promacta

WWeill Medical College of Cornell University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Wiskott-Aldrich syndrome1 trial

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT00909363·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Promacta. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Promacta compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Promacta. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Weill Medical College of Cornell University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWeill Medical College of Cornell University

Promacta

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Wiskott-Aldrich syndrome1 trial

References

Drug Info

Quick Facts

Related News